CDC. Yellow Fever. Atlanta, GA: Yellow Fever Vaccine Information for Healthcare Providers, CDC. [2019-1-19]. https://www.cdc.gov/yellowfever/.
[2]
Reinhardt B, Jaspert R, Niedrig M, Kostner C, L’Age-Stehr J. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol 1998;56:159 − 67. http://dx.doi.org/10.1002/(SICI)1096-9071(199810)56:2<159::AID-JMV10>3.0.CO;2-B.CrossRef
[3]
Lindsey NP, Schroeder BA, Miller ER, Braun MM, Hinckley AF, Marano N, et al. Adverse event reports following yellow fever vaccination. Vaccine 2008;26(48):6077 − 82. http://dx.doi.org/10.1016/j.vaccine.2008.09.009CrossRef
Jiangxi Provincial Center for Disease Control and Prevention (Jiangxi CDC) received an alert at 23:45 on November 7, 2019 from Nanchang Customs that yellow fever virus was detected in a foreign national.
On November 8, county, municipal, and provincial CDCs of Jiangxi Province carried out epidemiological investigations to show that the suspected case was found in a 35-year-old male patient from Addis Ababa, Ethiopia. On November 5, this patient began to have yellow-fever-like symptoms such as onset of fever, chills, and headache. At 16:11 on November 6, the patient and 12 accompanying colleagues arrived in Guangzhou where his temperature was measured at 38.0 ℃. Blood samples were collected by the Guangzhou Customs Laboratory and RT-PCR test results illustrated that the patient was experiencing yellow fever viremia. On November 7, the patient and his colleagues landed in Nanchang, and the Guangzhou Customs Laboratory alerted Nanchang Customs to inform Jiangxi CDC of the patient’s test result.
On November 8, the patient’s temperature had returned to normal and his other symptoms were relieved. None of the patient’s colleagues exhibited any symptoms. Jiangxi CDC tested the patient’s blood sample and the result showed that the yellow fever viremia disappeared. After 24 hours on November 9, the patient’s blood was tested for yellow fever virus a second time, and this result was negative again. Further investigation revealed that the patient received a yellow fever vaccination on November 1, 2019, as indicated by his immunization certificate.
On November 11, the Guangzhou Customs Laboratory finished RNA sequencing of the isolated virus and proved that the detected virus is a strain of the yellow fever vaccine virus. Based on evidence yielded by the investigation, including epidemiological history, onset of relatively mild symptoms, laboratory test results, and vaccination history, the patient’s symptoms were considered to be adverse reactions to the yellow fever vaccination.
CDC. Yellow Fever. Atlanta, GA: Yellow Fever Vaccine Information for Healthcare Providers, CDC. [2019-1-19]. https://www.cdc.gov/yellowfever/.
[2]
Reinhardt B, Jaspert R, Niedrig M, Kostner C, L’Age-Stehr J. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol 1998;56:159 − 67. http://dx.doi.org/10.1002/(SICI)1096-9071(199810)56:2<159::AID-JMV10>3.0.CO;2-B.
[3]
Lindsey NP, Schroeder BA, Miller ER, Braun MM, Hinckley AF, Marano N, et al. Adverse event reports following yellow fever vaccination. Vaccine 2008;26(48):6077 − 82. http://dx.doi.org/10.1016/j.vaccine.2008.09.009.